BACK TO ISCBH HOME

Abstracts

GET IN TOUCH

The abstracts from ICCBH 2026 have now been published online in JBMR® Plus (Journal of Bone and Mineral Research Plus) and can be found HERE.

We are delighted to have received over 270 abstract submissions for the 12th International Conference on Children’s Bone Health (ICCBH).  Thank you so much for all those authors who submitted their work!

The full abstract book for ICCBH 2026 is also available in pdf form. Please click the image on the right for access (on your mobile device it will be at the bottom of this page).

 

ICCBH 2026 will convene leading researchers, clinicians, and allied health professionals to share the latest advances in paediatric bone science, clinical care, and translational research. We welcome abstracts that contribute to the understanding, prevention, and treatment of bone disorders in children and adolescents.

Whether as an oral communication or a poster, presenting your work at an ICCBH meeting provides you with an opportunity to:

  • Showcase your current work
  • Get support and feedback from others
  • Raise your profile among colleagues internationally and from multiple disciplines
  • Widen your network to open up new opportunities for future collaborations
 

Abstract Presentation types

Oral communications

There will be six dedicated oral communications sessions.  Orals will be 10 minutes each (7 for the presentation and 3 for Q&A and discussion).

Click here for information for Speakers and Presenters

Printed Posters

Posters will be on boards for the entire meeting.  There will be dedicated sessions during the conference when presenters will be asked to be at their boards to discuss their data with other delegates.

Click here for information for Printed Poster Presenters 

 

Submission Guidelines

For detailed guidelines about submitting your abstract please click HERE.  These are also included in the online submission form.

Abstract Review process

Abstracts containing no data are unlikely to be accepted.  You must include results in your abstract unless you are describing a clinical case.

ICCBH 2026 abstracts are marked under blind conditions by a review panel on the basis of originality, scientific merit and significance.  Reviewers do not score abstracts when there is a potential or actual conflict of interest.  Submitted abstracts are primarily selected for oral/poster presentation on the basis of the scores achieved during the review process.  The Organisers reserve the right to make minimal adjustments to the final programme in order to maintain a breadth and balance of interests in the programme.

Publication

After the conference, abstracts will be published in JBMR® Plus (Journal of Bone and Mineral Research Plus).   

JBMR® Plus is the premier open access journal of the American Society for Bone and Mineral Research (ASBMR). A companion to internationally recognized title Journal of Bone and Mineral Research, JBMR® Plus aims to improve global musculoskeletal health by publishing innovative research covering endocrinology, geriatrics, orthopedics and rheumatology.

Embargo policy

The abstracts will be published on the ICCBH conference website one week before the start of ICBBH 2026.  The abstracts are therefore embargoed until the abstracts have been published.  Posters accepted for ICCBH 2026 are embargoed until the start of the Conference.

LATE BREAKING SUBMISSION IS NOW CLOSED

Dates to remember:

3 Nov 2025 – Abstract submission open

9 Feb 2026 – Deadline for abstracts

12 Mar 2026 – Confirmations to authors (UPDATED DATE)

8 Apr 2026 – Late breaking abstract submission opens

6 May 2026 – Deadline for late breaking abstracts

20 May 2026 – Confirmation to authors of late breaking abstracts

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE